EP2066381A1 - Inhalateur - Google Patents

Inhalateur

Info

Publication number
EP2066381A1
EP2066381A1 EP07801719A EP07801719A EP2066381A1 EP 2066381 A1 EP2066381 A1 EP 2066381A1 EP 07801719 A EP07801719 A EP 07801719A EP 07801719 A EP07801719 A EP 07801719A EP 2066381 A1 EP2066381 A1 EP 2066381A1
Authority
EP
European Patent Office
Prior art keywords
carrier
amino
formulation
inhaler according
inhaler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07801719A
Other languages
German (de)
English (en)
Inventor
Heinrich Kladders
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of EP2066381A1 publication Critical patent/EP2066381A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
    • A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A61M15/0053—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type or way of disposal
    • A61M15/0055—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type or way of disposal the used dosages being coiled
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/82—Internal energy supply devices
    • A61M2205/8275—Mechanical

Definitions

  • the present invention relates to an inhaler according to the preamble of claim 1.
  • the present invention relates to an inhaler for dispensing or inhaling a preferably pulverulent formulation, that is to say a powder inhaler.
  • a preferably pulverulent formulation that is to say a powder inhaler.
  • the formulation may in principle also be in the liquid phase, as a dispersion or in any other fluidizable form.
  • the formulation is a therapeutic agent or drug.
  • the formulation accordingly contains or consists of at least one active substance.
  • the formulation thus serves in particular for medical treatment or other therapeutic purposes.
  • the formulation is taken up by a carrier and in particular dosed into individual cans.
  • the present invention has for its object to provide a new inhaler, so that in a simple manner, a promotion, accurate metering and / or effective application of a particular powdered formulation is possible.
  • the carrier is thread-shaped. This allows in a very simple way a recording or promotion of the formulation by the carrier is conveyed or pulled, for example, by a formulation containing the reservoir.
  • the preferably rough surface absorbs the preferably powdery formulation.
  • the dosage of the formulation can be carried out particularly simply and accurately by appropriately advancing or conveying the carrier.
  • the dispensing or dispensing takes place in particular in that the carrier is moved in an area or section or with a section, preferably to vibrations, in particular like a string.
  • the discharge of the formulation is preferably carried out by an air flow, which flows against the carrier in particular transversely to its longitudinal extent.
  • air and air flow are preferably to be understood in a broader sense also to the effect that also another gas or a flow of another gas is included.
  • air is always used, since air is usually used as the gas for agitation and / or as the conveying medium for conveying the formulation after dissolution of or from the carrier or for dispersing the formulation.
  • Fig. 1 is a schematic section of an inhaler according to a first
  • FIG. 2 shows a schematic section of an inhaler according to a second embodiment.
  • Fig. 1 shows schematically the structure of a proposed inhaler 1 according to one embodiment.
  • the inhaler 1 is preferably designed to be portable and / or works in particular only mechanically.
  • the inhaler 1 is used for dispensing or inhaling a preferably powdered formulation 2 in the sense mentioned above.
  • the formulation 2 is present in particular as a bed or loose.
  • formulation 2 is contained in a reservoir 3 or the like.
  • the formulation 2 is metered or conveyed by means of a thread-shaped support 4.
  • the carrier 4 is preferably passed through this or the reservoir 3 with the formulation 2 for receiving the formulation 2 or can be moved or pulled through the reservoir 3.
  • the carrier 4 has, in particular, a correspondingly rough or open or otherwise suitable surface, in order to receive a particularly defined quantity of the formulation 2 in this case.
  • the recording by electrostatic forces o. The like. Can be supported.
  • the formulation 2 is preferably first taken up in the inhaler 1 or in sections or sequentially by the carrier 3.
  • the entire carrier 3 can also be provided with formulation 2 in advance or before insertion into the inhaler 1.
  • the carrier 4 can be moved or conveyed further into a metering chamber 5 after or during the reception of the formulation 2, in particular in sections or stepwise.
  • the carrier 4 releases the formulation 2 during or for inhalation. This is achieved or supported in particular by an air flow 6 and / or a movement, in particular oscillation, of at least one section of the carrier 4.
  • the carrier 4 is preferably assigned a manipulation device in order to move or vibrate the carrier 4 at least in sections. On the manipulation device will be discussed later in more detail.
  • the air flow 6 is preferably generated during inhalation or inhalation by a user, not shown, of the inhaler 1.
  • the air flow 6, for example, by a pump, - A -
  • the air flow 6 is used in particular for a discharge of the formulation 4 dispensed or metered by the carrier 4.
  • the formulation 2 dispersed in the air or in another conveying medium is preferably output via a mouthpiece 7 of the inhaler 1 or inhaled by a user (not shown).
  • a first coil 8 is preferably provided.
  • the carrier 4 is guided by the coil 8 through the reservoir 3 and the metering chamber 5.
  • the carrier 4 is rewound in the inhaler 1, in particular of a second coil 9 in the illustrated example.
  • this guide elements such as guide rollers 10 o. The like., To be assigned.
  • the inhaler 1 preferably has a suitable drive device (not shown).
  • the drive means acts for example on the second coil 9, so that a gradual winding and thus further movement of the carrier 4 is made possible.
  • the drive device is preferably manually operable, for example by opening the inhaler 1, the mouthpiece 7 o.
  • the drive device can work in any desired manner.
  • the like. That the carrier 4 is moved on quasi automatically. In this case, in particular, only a triggering is required to move the carrier 4 a step or section, if desired, for example, immediately before the next inhalation o.
  • Such a drive device for example, by an integrated into the second coil 9 or this associated spring, in particular a watch spring o. The like., To be realized.
  • the drive device for example, but also work electrically.
  • the carrier 4 or the first and / or second coil 8, 9 and / or the drive device o.
  • the manipulation device is preferably designed such that the carrier 4 is moved or plucked and / or caused to vibrate by plucking.
  • the manipulation device preferably has a plucking element 1 1, which in particular can be operated manually, in the illustrated embodiment by means of a handle 12.
  • the plucking element 11 can engage behind the carrier 4 in a freely tensioned region within the metering chamber 5 and deflect the carrier 4 by means of the handle 12, so that after release of the handle 12 - and in particular return by a return spring 13 - the carrier 4 in particular can oscillate freely in the manner of a string, as indicated by dashed lines in Fig. 1.
  • the carrier 4 is thus moved in particular transversely to its longitudinal extension, particularly preferably set into oscillation.
  • the discharge of the formulation 2 then takes place simultaneously or subsequently, in particular by means of the air flow 6 or by means of another suitable conveying medium.
  • the air flow 6 can also act and / or move the carrier 4 directly and / or indirectly.
  • a second embodiment of the proposed inhaler 1 will be explained below with reference to FIG. Only essential differences from the first embodiment will be explained below, so that in particular the previous remarks and explanations apply correspondingly or additionally to the second embodiment.
  • the inhaler 1 or the manipulation device has a vibrating body 14, which in particular can be moved or set into oscillation by the air flow 6.
  • the vibrating body 14 is preferably formed substantially spherical. However, it may also have any other suitable shape, for example an elongated, egg-shaped, cylindrical or rotationally symmetrical shape.
  • the oscillating body 14 is received in a region of the metering chamber 5 or a separate space 15 to which the air flow 6 can be supplied via a channel 16.
  • the channel 16 opens to the area or space 15, in particular with a cross-section which is reduced in comparison with and against the oscillating body 14.
  • other arrangements are possible here.
  • the vibrating body 14 is reciprocated by the air flow 6 and, in particular, set in oscillation, more preferably along the main flow direction.
  • the geometric conditions correspond to the information in EP 0 147 755 A2, which is referred to in this regard as supplementary disclosure.
  • the reciprocating movement of the vibrating body 14 is effected by the so-called Bernoulli effect.
  • the vibrating body 14 strikes the carrier 4 in particular transversely to the longitudinal extent.
  • the carrier 4 is correspondingly displaced by the movement or oscillation of the vibrating body 14 in a preferably flutter-like or wave-like movement or oscillation. This leads to the desired movement of the carrier 4 in a very effective manner in order to assist or to achieve a release of the formulation 2 from the carrier 4 or a dispersion of the formulation 2.
  • the oscillating body 14 acts on the carrier 4 in a striking manner.
  • other mechanisms of action may also be effective.
  • the air flow 6 also forms the conveying medium in order to disperse and / or convey the formulation 2 dissolved by the carrier 4, in particular by its movement, and preferably via the mouthpiece 7 of FIG Dispensing inhaler 1 and output to a user, not shown.
  • the air flow 6 can also be generated or provided by a pump, compressed air or the like.
  • the carrier 4 may already be provided with the formulation 2 in advance - ie before insertion or installation in the inhaler 1 - or be.
  • the reservoir 3 for the formulation 2 can be omitted.
  • the carrier 4 preferably received or wound in the first coil 8 may already be provided with the formulation 2.
  • the formulation 2 may, for example, also be applied as a coating to the surface of the carrier 4 or cover it partially or completely.
  • the carrier 4 is formed according to the proposal thread-shaped. This allows in particular a simple unwinding and winding and a simple guide.
  • filamentary is to be understood in particular as meaning that the cross section is at least substantially circular. In a broader sense, however, the term “thread-like” preferably also includes other cross-sectional shapes. In the limiting case, the carrier 4 may also have an at least substantially rectangular cross-section and / or optionally be band-shaped.
  • the support 4 is particularly preferably constructed from a plurality of fiber elements, fibers, filaments or the like and / or provided with an open or non-closed surface.
  • the carrier 4 may in principle also be a monofilament, a single fiber or the like, in particular if the surface is appropriately or suitably treated. is to allow for adhering and / or receiving the formulation 2 in the desired or required manner.
  • the inhaler particularly preferably works only mechanically.
  • the inhaler 1 can also operate electrically or electronically and / or contain such components or components. This applies in particular to a trigger device for triggering a discharge of formulation 2 or the duration of inhalation, a drive, a pump, a counter, a lock, a control device or the like.
  • inhaler is preferably also to be understood in a broader sense as including other dispensers or nebulizers, in particular for medical or other therapeutic purposes.
  • Preferred ingredients and / or compositions of preferably medicinal formulation 2 are listed below. As already mentioned, these are in particular powders or liquids in the widest sense. Particularly preferred in formulation 2 are:
  • W is a pharmacologically active agent and (for example) selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, dopamine agonists, HIV antihistamines, PAF- Antagonists and PI3 kinase inhibitors.
  • two or three combinations of W can be combined and used for application in the device according to the invention.
  • W represents a betamimetics combined with anticholinergics, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists
  • W represents an anticholinergic agent combined with a betamimetics, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4- antagonists
  • W represents an EGFR inhibitor combined with a LTD4 antagonist.
  • Preferred betamimetics are compounds selected from the group consisting of albuterol, arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, isoetharines, isoprenaline, levosalbutamol, mabuterol , Meluadrine, Metaproterenol, Orciprenaline, Pirbuterol, Procaterol, Reproterol, Rimiterol, Ritodrine, Salmefamol, Salmeterol, Soterenol, Sulphone terol, Terbutaline, Tiaramide, Tolubuterol, Zinterol, CHF-1035, HO-KU-81, KUL-1248 and
  • N-adamantan-2-yl-2- (3- ⁇ 2- [2-hydroxy-2- (4-hydroxy-3-hydroxymethylphenyl) -ethylamino] -propyl ⁇ -phenyl) -acetamide optionally in the form of their racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates.
  • the acid addition salts of the betamimetics are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydro fumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • Preferred anticholinergic compounds are compounds which are selected from the group consisting of tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt, trospi - salt, preferably the chloride salt, tolterodine.
  • the cations are the pharmacologically active ingredients.
  • the aforementioned salts may preferably contain chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate , Succinate, benzoate or p-toluenesulfonate, with chloride, bromide, iodide, sulfate, methanesulfonate or p-toluenesulfonate being preferred as counterions.
  • the chlorides, bromides, iodides and methanesulfonates are particularly preferred.
  • anticholinergics are selected from the salts of the formula AC-I
  • X is a single negatively charged anion, preferably an anion selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-Toluenesulfonate, preferably a singly negatively charged anion, more preferably an anion selected from the group consisting of fluoride, chloride, bromide, methanesulfonate and p-toluenesulfonate, most preferably bromide, optionally in the form of their racemates, enantiomers or hydrates Significance are those drug combinations that contain the enantiomers of the formula AC-1-en
  • the compound of the formula AC-2 can also be present in the form of the free base AC-2-base.
  • Preferred corticosteroids are compounds selected from the group consisting of beclomethasone, betamethasone, budesonide, butixocort, ciclesonide, deflazacort, dexamethasone, etiprednol, flunisolide, fluticasone, loteprednol, mometasone, prednisolone, prednisone, rofleponide, Triamcinolone, RPR-106541, NS-126, ST-26 and
  • Examples of possible salts and derivatives of steroids may be: alkali metal salts, such as, for example, sodium or potassium salts, sulfobenzoates, phosphates, isonicotinates, acetates, dichloroacetates, propionates, dihydrogen phosphates, palmitates, pivalates or even furoates.
  • alkali metal salts such as, for example, sodium or potassium salts, sulfobenzoates, phosphates, isonicotinates, acetates, dichloroacetates, propionates, dihydrogen phosphates, palmitates, pivalates or even furoates.
  • Preferred PDE4 inhibitors are compounds selected from the group consisting of enprofylline, theophylline, roflumilast, ariflo (cilomilast), tofimilast, pumafentrin, lirilmast, arofylline, atizoram, D-4418, bay 198004, BY343, CP-325,366, D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T-2585, V-11294A, Cl-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370 and
  • the acid addition salts of the betamimetics are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydro fumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro p-toluenesulfonate.
  • Preferred LTD4 antagonists here are compounds which are selected from the group consisting of monoglucast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF- 5078, VUF-K-8707, L-733321 and
  • the acid addition salts of the betamimetics are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydro fumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro p-toluenesulfonate.
  • Salts or derivatives which the LTD4 antagonists may be able to form are understood to mean alkali metal salts such as, for example, sodium or potassium salts, alkaline earth metal salts, sulfobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or even furoates.
  • alkali metal salts such as, for example, sodium or potassium salts, alkaline earth metal salts, sulfobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or even furoates.
  • Preferred EGFR inhibitors are compounds selected from the group consisting of cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 and
  • the acid addition salts of the betamimetics are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydro fumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro p-toluenesulfonate.
  • Preferred dopamine agonists are compounds which are selected from the group consisting of bromocriptine, cabergoline, alpha-dihydroergocryptine, lisuride, pergolide, pramipexole, rooxinol, ropinirole, talipexol, terguride and viozan, optionally in the form of their racemates , Enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates.
  • the acid addition salts of the betamimetics are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate ,
  • Hl -Antihistaminika here are preferably compounds used, which are selected from the group consisting of epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimetindene, clemastine, bamipine, Cexchlorpheniramin, phenamine, doxylamine , Chlorphenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratidine and meclocine, optionally in the form of their racemates, enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates.
  • the acid addition salts of the betamimetics are preferably selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydrogen maleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate.
  • inhalable macromolecules can be used as disclosed in EP 1 003 478 A1 or CA 2297174 A1.
  • the compound may be derived from the group of derivatives of ergot alkaloids, triptans, CGRP inhibitors, phosphodiesterase V inhibitors, optionally in the form of their racemates, enantiomers or diastereomers, optionally in the form of their pharmacologically acceptable acid addition salts, their solvates and / or hydrates.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un inhalateur (1) pour l'inhalation d'une formulation (2), cet inhalateur comprenant un support (4) filiforme servant à doser et/ou transporter la formulation.
EP07801719A 2006-09-20 2007-08-17 Inhalateur Withdrawn EP2066381A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006044755A DE102006044755A1 (de) 2006-09-20 2006-09-20 Inhalator
PCT/EP2007/007269 WO2008034505A1 (fr) 2006-09-20 2007-08-17 Inhalateur

Publications (1)

Publication Number Publication Date
EP2066381A1 true EP2066381A1 (fr) 2009-06-10

Family

ID=38691766

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07801719A Withdrawn EP2066381A1 (fr) 2006-09-20 2007-08-17 Inhalateur

Country Status (4)

Country Link
US (1) US20100059051A1 (fr)
EP (1) EP2066381A1 (fr)
DE (1) DE102006044755A1 (fr)
WO (1) WO2008034505A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010135340A2 (fr) * 2009-05-18 2010-11-25 3M Innovative Properties Company Inhalateurs de poudre sèche
CA2779488A1 (fr) * 2009-11-12 2011-05-19 Stc.Unm Inhalateur pour poudre seche avec un element de dispersion par flottement
JP6050758B2 (ja) * 2010-12-07 2016-12-21 レスピラ セラピューティクス インコーポレイテッドＲｅｓｐｉｒａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 乾燥粉末吸入器及びその作動方法
US10463815B2 (en) 2012-02-21 2019-11-05 Respira Therapeutics, Inc. Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents
TR201807942T4 (tr) * 2012-09-26 2018-06-21 Boehringer Ingelheim Int İnhalatör.
CA2972826C (fr) 2015-01-14 2023-09-12 Respira Therapeutics, Inc. Procedes et dispositifs de dispersion de poudre
WO2018071427A1 (fr) * 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhalateur et ses méthodes d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8909891D0 (en) * 1989-04-28 1989-06-14 Riker Laboratories Inc Device
ATE138814T1 (de) * 1989-04-28 1996-06-15 Riker Laboratories Inc Inhalationsvorrichtung für trockenpulver
GB9203761D0 (en) * 1992-02-21 1992-04-08 Innovata Biomed Ltd Inhaler
GB9314614D0 (en) * 1993-07-14 1993-08-25 Minnesota Mining & Mfg Dry powder inhalers
SE9903824D0 (sv) * 1999-10-22 1999-10-22 Medifront Ab Anordning för avgivning av multipla doser för pulverinhalatorer och motsvarande avgivningsförfarande

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008034505A1 *

Also Published As

Publication number Publication date
US20100059051A1 (en) 2010-03-11
DE102006044755A1 (de) 2008-04-10
WO2008034505A1 (fr) 2008-03-27

Similar Documents

Publication Publication Date Title
EP2015811B1 (fr) Pulvérisateur et procédé de pulverisation d'un fluide
EP2004263B1 (fr) Dispositif d'émission de médicaments et magasins à médicaments
EP3508239B1 (fr) Adaptateur, dispositif d'inhalation et pulvérisateur
EP2066382B1 (fr) Doseur à piston
EP2066380B1 (fr) Inhalateur
EP2029205A1 (fr) Pulvérisateur
EP2007459A1 (fr) Inhalateur
WO2007141201A1 (fr) Adaptateur avec raccord pour pulvérisateur
EP2135632A1 (fr) Inhalateur
DE102006043637A1 (de) Zerstäuber
EP2007457A1 (fr) Inhalateur
EP2007349B1 (fr) Formulations de suspensions pour aérosols utilisant du tg 227 ea ou du tg 134 a comme propulseur
WO2007048763A1 (fr) Inhalateur avec embout ayant une fonction de protection microbiologique
DE102007036411A1 (de) Pulverinhalator
WO2008034505A1 (fr) Inhalateur
EP2424603A1 (fr) Dispositif d'inhalation
EP2001601B1 (fr) Aérosols de dosage pour l'administration de préparations pharmaceutiques
EP2004261B1 (fr) Dispositif de distribution de médicaments
EP2004260A1 (fr) Magasin à médicaments et dispositif et procédé pour l'ouvrir; inhalateur à poudre à doses multiples
DE102007033861A1 (de) Pulverinhalator
EP2198972A1 (fr) Réservoir et gicleur

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090420

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110301